Over the past month, the ASX has gone virtually nowhere, with the All Ordinaries (INDEXASX: XAO) (ASX: XAO) down 0.4% and the S&P/ASX 200 (INDEXASX: XJO) (ASX: XJO) up 0.5%.
But that doesn’t mean all stocks listed on the Australian Stock Exchange have gone nowhere. In fact, 10 companies have seen their share prices soar by more than 50%, and 4 of these have more than doubled.
Cynata Therapeutics Ltd (ASX: CYP) has leapt 228% since early February to $1.18. The stem cell research company achieved a major breakthrough, achieving commercial-scale manufacture of stem cell products. As you can well imagine, that has major implications if Cynata can go on and commercialise its technology.
AtCor Medical Holdings Limited (ASX: ACG) is up 120% to 21 cents. AtCor received Category 1 approval for its SphygmoCor blood pressure system in the US. Colleague Brendon Lau covered the news in more detail here.
Cyclopharm Limited (ASX: CYC) jumped 116.9% to 64 cents, after reporting record sales of $12 million and an record net profit of $4m – although that included a $2.65 million legal settlement. Cyclopharm is a nuclear medicine company, with products including Technegas for lung imaging. Has the company turned the corner like CEO James McBrayer thinks it has?
Cokal Ltd (ASX: CKA) has seen its shares soar 128.6% to 10 cents, despite the company being a coal explorer. In late February, Cokal received construction and operational approval for its Bumi Barito Mineral (BBM) Project port facilities in Indonesia. BBM is expected to produce a premium coking coal over a period of more than 15 years.
TNG Limited (ASX: TNG) has gained 77.8% to trade around 17 cents currently. TNG is focused on developing its flagship Mount Peak Vanadium-Titanium-Iron project near Alice Springs, which the company says can deliver revenues of $13.6 billion. Yesterday TNG signed an offtake agreement with Korean metals group WOOJIN IND. Co. for up to 60% of forecast production.
Aeris Environmental Ltd (ASX: AEI) shares have climbed 50.7% to trade around 51 cents currently. Aeris is an expert in the removal of bacteria and mould that naturally builds up in air-conditioning, cold storage and bulk water systems and then protects the asset from further recontamination. Aeris recently reported strong growth in purchase orders and potential pipeline of large scale projects.
1-Page Limited (ASX: 1PG) has jumped 66.7% to $1.65 after the company signed a number of major deals, including giant US retailer Amazon for its 1-Page sourcing and referral engine. 1-Page offers companies a new way to hire prospective employees.
Joyce Corporation Ltd (ASX: JYC) has gained 50.8% to trade at 95 cents. The company owns a chain of bedding stores under the BedShed brand. Joyce recently sold a property for $25 million, and the board is considering a suitable return to shareholders of the settlement proceeds, expected to be a franked special dividend of 5 cents per share each year for the next three years. Joyce is forecast to pay 10.5 cents in total this year.
Anatarra Lifesciences Ltd (ASX: ANR) is up 57.6% to 52 cents. Anatarra develops non-antibiotic solutions for gastrointestinal diseases in animals and humans, and recently reported a successful trial on a pig farm of its Detach product. Anatarra is now focused on registering Detach in Europe and the USA, and hopes to launch Detach in 2016 in Australia.
Last but not least is Digital CC Ltd (ASX: DCC) which is up 66.7% to 14 cents. The company is a digital payments company – the first bitcoin focused company listed on a major exchange. Bitcoin is a digital currency that is usually in the news for the wrong reasons, and there’s no guarantee that Bitcoin will be successful.
Biotech stocks are highly risky and could just as easily fall 50% in a day. Here's a Foolish alternative or three...
The Australian Financial Review says "good quality Australian shares that have a long history of paying dividends are a real alternative to a term deposit.” Get “3 Stocks for the Great Dividend Boom” in our special FREE report. Click here now to find out the names, stock symbols, and full research for three of our favourite income ideas, all completely free!
Motley Fool writer/analyst Mike King doesn't own shares in any companies mentioned. You can follow Mike on Twitter @TMFKinga